Cargando…

Development of indicators for assessing rational drug use to treat community-acquired pneumonia in children in hospitals and clinics: A modified Delphi study

Community-acquired pneumonia (CAP) is a common infectious disease in children. Rational drug use (RDU) is an important approach to reducing the disease burden and mortality rate of CAP in children. There are no monitoring indicators for assessing RDU in children. This study aimed to develop a set of...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wenrui, Zeng, Linan, Li, Jialian, Huang, Liang, Gui, Ge, Song, Jie, Chen, Lina, Jiang, Lucan, Zhang, Lingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758202/
https://www.ncbi.nlm.nih.gov/pubmed/29390500
http://dx.doi.org/10.1097/MD.0000000000009308
_version_ 1783290963594051584
author Li, Wenrui
Zeng, Linan
Li, Jialian
Huang, Liang
Gui, Ge
Song, Jie
Chen, Lina
Jiang, Lucan
Zhang, Lingli
author_facet Li, Wenrui
Zeng, Linan
Li, Jialian
Huang, Liang
Gui, Ge
Song, Jie
Chen, Lina
Jiang, Lucan
Zhang, Lingli
author_sort Li, Wenrui
collection PubMed
description Community-acquired pneumonia (CAP) is a common infectious disease in children. Rational drug use (RDU) is an important approach to reducing the disease burden and mortality rate of CAP in children. There are no monitoring indicators for assessing RDU in children. This study aimed to develop a set of indicators to assess RDU to treat CAP in children in hospitals and clinics using a modified Delphi method. Initial indicators were generated based on a systematic review of guidelines and studies investigating CAP in children. A 3-round modified Delphi process in the form of an email survey combined with round-table discussion was then carried out, and an analytic hierarchy process (AHP) was applied to determine the weight of each indicator. A total of 24 and 8 experts were invited to participate in the email survey and round-table discussion, respectively. A consensus was reached after 3 rounds of the Delphi survey. Three first-rank indicators and 23 second-rank indicators were developed, and each indicator was weighted. The first-rank indicators comprised drug choice (45.5%), drug usage and dosage (36.4%), and the duration of drug therapy (18.2%); the second-rank indicators were indicators related to antibiotics (63.6%), antiviral agents (18.2%), traditional Chinese medicines (4.5%), and adjuvant drugs (13.6%). The weight value of drug selection was the highest, followed by the values of drug usage and dosage and the duration of drug therapy. The developed indicator set constitutes the first set intended to assess RDU to treat CAP in children in hospitals (including community hospitals) and clinics. The indicators were based on drug selection, drug usage and dosage and duration of drug therapy, which are associated with most therapeutic drugs for CAP in children. Monitoring these indicators will guide people towards the promotion of RDU in the absence of drug monitoring indicators for CAP. Furthermore, the indicator set constitutes a methodological reference for the development of other indicator sets.
format Online
Article
Text
id pubmed-5758202
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-57582022018-01-29 Development of indicators for assessing rational drug use to treat community-acquired pneumonia in children in hospitals and clinics: A modified Delphi study Li, Wenrui Zeng, Linan Li, Jialian Huang, Liang Gui, Ge Song, Jie Chen, Lina Jiang, Lucan Zhang, Lingli Medicine (Baltimore) 6200 Community-acquired pneumonia (CAP) is a common infectious disease in children. Rational drug use (RDU) is an important approach to reducing the disease burden and mortality rate of CAP in children. There are no monitoring indicators for assessing RDU in children. This study aimed to develop a set of indicators to assess RDU to treat CAP in children in hospitals and clinics using a modified Delphi method. Initial indicators were generated based on a systematic review of guidelines and studies investigating CAP in children. A 3-round modified Delphi process in the form of an email survey combined with round-table discussion was then carried out, and an analytic hierarchy process (AHP) was applied to determine the weight of each indicator. A total of 24 and 8 experts were invited to participate in the email survey and round-table discussion, respectively. A consensus was reached after 3 rounds of the Delphi survey. Three first-rank indicators and 23 second-rank indicators were developed, and each indicator was weighted. The first-rank indicators comprised drug choice (45.5%), drug usage and dosage (36.4%), and the duration of drug therapy (18.2%); the second-rank indicators were indicators related to antibiotics (63.6%), antiviral agents (18.2%), traditional Chinese medicines (4.5%), and adjuvant drugs (13.6%). The weight value of drug selection was the highest, followed by the values of drug usage and dosage and the duration of drug therapy. The developed indicator set constitutes the first set intended to assess RDU to treat CAP in children in hospitals (including community hospitals) and clinics. The indicators were based on drug selection, drug usage and dosage and duration of drug therapy, which are associated with most therapeutic drugs for CAP in children. Monitoring these indicators will guide people towards the promotion of RDU in the absence of drug monitoring indicators for CAP. Furthermore, the indicator set constitutes a methodological reference for the development of other indicator sets. Wolters Kluwer Health 2017-12-22 /pmc/articles/PMC5758202/ /pubmed/29390500 http://dx.doi.org/10.1097/MD.0000000000009308 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle 6200
Li, Wenrui
Zeng, Linan
Li, Jialian
Huang, Liang
Gui, Ge
Song, Jie
Chen, Lina
Jiang, Lucan
Zhang, Lingli
Development of indicators for assessing rational drug use to treat community-acquired pneumonia in children in hospitals and clinics: A modified Delphi study
title Development of indicators for assessing rational drug use to treat community-acquired pneumonia in children in hospitals and clinics: A modified Delphi study
title_full Development of indicators for assessing rational drug use to treat community-acquired pneumonia in children in hospitals and clinics: A modified Delphi study
title_fullStr Development of indicators for assessing rational drug use to treat community-acquired pneumonia in children in hospitals and clinics: A modified Delphi study
title_full_unstemmed Development of indicators for assessing rational drug use to treat community-acquired pneumonia in children in hospitals and clinics: A modified Delphi study
title_short Development of indicators for assessing rational drug use to treat community-acquired pneumonia in children in hospitals and clinics: A modified Delphi study
title_sort development of indicators for assessing rational drug use to treat community-acquired pneumonia in children in hospitals and clinics: a modified delphi study
topic 6200
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758202/
https://www.ncbi.nlm.nih.gov/pubmed/29390500
http://dx.doi.org/10.1097/MD.0000000000009308
work_keys_str_mv AT liwenrui developmentofindicatorsforassessingrationaldrugusetotreatcommunityacquiredpneumoniainchildreninhospitalsandclinicsamodifieddelphistudy
AT zenglinan developmentofindicatorsforassessingrationaldrugusetotreatcommunityacquiredpneumoniainchildreninhospitalsandclinicsamodifieddelphistudy
AT lijialian developmentofindicatorsforassessingrationaldrugusetotreatcommunityacquiredpneumoniainchildreninhospitalsandclinicsamodifieddelphistudy
AT huangliang developmentofindicatorsforassessingrationaldrugusetotreatcommunityacquiredpneumoniainchildreninhospitalsandclinicsamodifieddelphistudy
AT guige developmentofindicatorsforassessingrationaldrugusetotreatcommunityacquiredpneumoniainchildreninhospitalsandclinicsamodifieddelphistudy
AT songjie developmentofindicatorsforassessingrationaldrugusetotreatcommunityacquiredpneumoniainchildreninhospitalsandclinicsamodifieddelphistudy
AT chenlina developmentofindicatorsforassessingrationaldrugusetotreatcommunityacquiredpneumoniainchildreninhospitalsandclinicsamodifieddelphistudy
AT jianglucan developmentofindicatorsforassessingrationaldrugusetotreatcommunityacquiredpneumoniainchildreninhospitalsandclinicsamodifieddelphistudy
AT zhanglingli developmentofindicatorsforassessingrationaldrugusetotreatcommunityacquiredpneumoniainchildreninhospitalsandclinicsamodifieddelphistudy